Healthcare | Tuesday 23 October, 2018 1:00 pm |

In collaboration with the Saudi Ministry of Health and the Saudi Heart Failure Group, and under the auspices of His Excellency Dr. Tarif Al-Aamy, Undersecretary of the Ministry of Health for Therapeutic Affairs, the "Hearts" conference, targeting the cardiac failure, was organized by the Saudi PharmaceuticalDistribution Co. Ltd., one of Novartis group of companies, The conference was attended by  physicians and cardiologists, other healthcare professionals from all over Saudi Arabia, and media representatives.

On the margin of the Conference, Dr. Waleed Al Habeeb, President of Saudi Heart FailureGroup, shed light on the heart failure disease, its upward rates, and the risks of mortality among the patients, which exceed the mortality rates of cancerous people. Dr. Waleed stressing the significant role that can be played by globally unifying the developmental efforts in order to identify the causes and management of heart failure disease and realize the most effective ways in treating it. "This conference is part of those efforts, as it acts as a platform embracing right information about heart failure,and a valuable initiative in which all the efforts of the committed companies and other entities are mutually exertedto help improve the patients' quality of life and to innovate unbeaten medical solutions, in line with Saudi Arabia's Vision 2030 the objectives of the National Transition Program 2020", Dr. Waleed added.

A diversity of topics relevant to heart failure were covered during the 2 day conference, includingpapers and lectures delivered by a group of physicians and cardiologists, from inside the Kingdom and abroad. The issues touched many significant areas, including but not limited to, management of cardiac failure, ways to care for the disease beyond therapeutic norms, epidemiology and its direct link to the disease, relationship between Sympathetic Nervous System and the heart failure, quality of the devises used in heart failure's treatment. 

 

The conference also featured some workshops introduced by a group of cardiologists together with Dr. Mohammed Habab, Dr. Shukri Al-Saif, and Dr. Waleed Al Habeeb. The workshops focused on the strategies that should be adopted to provide heart failure patients with high level of medical treatment, significance of launching initiatives on the disease's remedy, the latest innovative solutions in the field, the need to form a multidisciplinary team to handle the heart failure issues, challenges in the management of patients' over-medication, efforts to boost patient's therapeutic journey from the moment he enters the hospital until his leaves, and the physiology of disease from the latest global trends in this regard, to successful clinical practices. 

 

It's worth mentioning that Novartis has earlier produced a new medicine that have been central to treating heart failure. the medicine proved remarkably effective in motivating the heart muscle, stimulating the Sympathetic Nervous System, and improving the body's natural defenses against heart failure.